On Friday, Genmab’s partner released more data from the phase III MAIA study with Darzalex (daratumumab). This data should not have a major effect on the Genmab share price.
"From an interest rate perspective, you shouldn’t put too much into it. However, this says something about the effect and responses connected with Darzalex," states Sydbank Chief Equity Analyst Søren Løntoft Hansen.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.